NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

RecruitingPhase 1

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Conditions: Carcinoma, Non-small-Cell Lung

Interventions: JNJ-86974680, Cetrelimab, Radiation Therapy

Countries: United States, Germany, South Korea, Spain

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
* Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed
* Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\])
* Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
* For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy
* For Cohort C of Part 2: Treatment naïve
* Adequate organ function

Exclusion Criteria:

* Active central nervous system (CNS) disease involvement
* Active autoimmune disease
* Active infection
* History of solid organ or hematologic stem cell transplantation

Locations (15)

Newnan, Georgia, United States
Hackensack, New Jersey, United States
Buffalo, New York, United States
New York, New York, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Fairfax, Virginia, United States
Berlin, Germany
Giessen, Germany
Seoul, South Korea
Seoul, South Korea
Barcelona, Spain
Barcelona, Spain
Madrid, Spain
Valencia, Spain